RGNX
insider transactionsREGENXBIO Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-15.3K
0 buy · 15.3K sell
Net value · 90d
-$168.7K
$0 in · $168.7K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
1
0 buy · 15.3K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +44%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +2%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Sell·S
Chief Medical Officer · 10b5-1
$168.7K
15.3K sh · $11.02
Own -6%
-
Grant·A
Director
$0
24.4K sh
Own +10%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 29, 2026 | Jennifer Zachary | Grant A | 46.6K | $0 |
| May 29, 2026 | Jennifer Zachary | Grant A | 9.8K | $0 |
| May 29, 2026 | Daniel Tasse | Grant A | 46.6K | $0 |
| May 29, 2026 | Daniel Tasse | Grant A | 9.8K | $0 |
| May 29, 2026 | David C Stump | Grant A | 46.6K | $0 |
| May 29, 2026 | David C Stump | Grant A | 9.8K | $0 |
| May 29, 2026 | Kenneth T. Mills | Grant A | 46.6K | $0 |
| May 29, 2026 | Kenneth T. Mills | Grant A | 9.8K | $0 |
| May 29, 2026 | George V Migausky | Grant A | 46.6K | $0 |
| May 29, 2026 | George V Migausky | Grant A | 9.8K | $0 |
| May 29, 2026 | Argeris N Karabelas | Grant A | 46.6K | $0 |
| May 29, 2026 | Argeris N Karabelas | Grant A | 9.8K | $0 |
| May 29, 2026 | Alexandra Glucksmann | Grant A | 46.6K | $0 |
| May 29, 2026 | Alexandra Glucksmann | Grant A | 9.8K | $0 |
| May 29, 2026 | Allan M. Fox | Grant A | 46.6K | $0 |
| May 29, 2026 | Allan M. Fox | Grant A | 9.8K | $0 |
| May 29, 2026 | Jean Bennett | Grant A | 46.6K | $0 |
| May 29, 2026 | Jean Bennett | Grant A | 9.8K | $0 |
| May 11, 2026 | Steve Pakola 10b5-1 | Sell S | 15.3K | $168.7K |
| Apr 20, 2026 | Jean Bennett | Grant A | 24.4K | $0 |
About RGNX insider trading
This page tracks insider transactions for REGENXBIO Inc. (RGNX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.